October 12, 2026- Abbott announced new real-world evidence showing that completion of multitarget stool DNA (mt-sDNA) screening was associated with approximately 54% lower colorectal cancer incidence and 45% lower odds of death following a colorectal cancer diagnosis. The findings are among 13 abstracts highlighting new colorectal cancer screening research being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place Oct. 9-14 in Nashville.